Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma

Detalhes bibliográficos
Autor(a) principal: Pimenta,Rita
Data de Publicação: 2021
Outros Autores: Costa-Rosa,Joaninha, Cravo,Mariana, Rafael,Margarida, Moura,Cecília
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100001
Resumo: ABSTRACT: Targeted therapy and immunotherapy have markedly improved prognosis of advanced melanoma patients. With expanded use of these drugs, a range of cutaneous adverse events has emerged. Although the vast majority of adverse events are low-grade, they many cause significant morbidity and can affect patients' quality of life. Early diagnosis and prompt intervention may prevent unnecessary discontinuation of life-saving anticancer therapies. In this article, we review the cutaneous adverse events of small molecules and monoclonal antibodies used for the therapy of melanoma and discuss their pathophysiology and recommendations for prevention and management of these adverse events.
id RCAP_cf0357b6f69de908a04d68d410c46747
oai_identifier_str oai:scielo:S2182-23952021000100001
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with MelanomaDrug-Related Side Effects and Adverse ReactionsImmunotherapy/adverse effectsMelanomaMolecular Targeted TherapySkin/drug effectsSkin Diseases/chemically inducedABSTRACT: Targeted therapy and immunotherapy have markedly improved prognosis of advanced melanoma patients. With expanded use of these drugs, a range of cutaneous adverse events has emerged. Although the vast majority of adverse events are low-grade, they many cause significant morbidity and can affect patients' quality of life. Early diagnosis and prompt intervention may prevent unnecessary discontinuation of life-saving anticancer therapies. In this article, we review the cutaneous adverse events of small molecules and monoclonal antibodies used for the therapy of melanoma and discuss their pathophysiology and recommendations for prevention and management of these adverse events.Sociedade Portuguesa de Dermatologia e Venereologia2021-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100001Revista da Sociedade Portuguesa de Dermatologia e Venereologia v.79 n.1 2021reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100001Pimenta,RitaCosta-Rosa,JoaninhaCravo,MarianaRafael,MargaridaMoura,Cecíliainfo:eu-repo/semantics/openAccess2024-02-06T17:26:29Zoai:scielo:S2182-23952021000100001Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:31:36.359322Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
title Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
spellingShingle Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
Pimenta,Rita
Drug-Related Side Effects and Adverse Reactions
Immunotherapy/adverse effects
Melanoma
Molecular Targeted Therapy
Skin/drug effects
Skin Diseases/chemically induced
title_short Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
title_full Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
title_fullStr Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
title_full_unstemmed Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
title_sort Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
author Pimenta,Rita
author_facet Pimenta,Rita
Costa-Rosa,Joaninha
Cravo,Mariana
Rafael,Margarida
Moura,Cecília
author_role author
author2 Costa-Rosa,Joaninha
Cravo,Mariana
Rafael,Margarida
Moura,Cecília
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Pimenta,Rita
Costa-Rosa,Joaninha
Cravo,Mariana
Rafael,Margarida
Moura,Cecília
dc.subject.por.fl_str_mv Drug-Related Side Effects and Adverse Reactions
Immunotherapy/adverse effects
Melanoma
Molecular Targeted Therapy
Skin/drug effects
Skin Diseases/chemically induced
topic Drug-Related Side Effects and Adverse Reactions
Immunotherapy/adverse effects
Melanoma
Molecular Targeted Therapy
Skin/drug effects
Skin Diseases/chemically induced
description ABSTRACT: Targeted therapy and immunotherapy have markedly improved prognosis of advanced melanoma patients. With expanded use of these drugs, a range of cutaneous adverse events has emerged. Although the vast majority of adverse events are low-grade, they many cause significant morbidity and can affect patients' quality of life. Early diagnosis and prompt intervention may prevent unnecessary discontinuation of life-saving anticancer therapies. In this article, we review the cutaneous adverse events of small molecules and monoclonal antibodies used for the therapy of melanoma and discuss their pathophysiology and recommendations for prevention and management of these adverse events.
publishDate 2021
dc.date.none.fl_str_mv 2021-03-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100001
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100001
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Dermatologia e Venereologia
publisher.none.fl_str_mv Sociedade Portuguesa de Dermatologia e Venereologia
dc.source.none.fl_str_mv Revista da Sociedade Portuguesa de Dermatologia e Venereologia v.79 n.1 2021
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137376951336960

Registros relacionados